Log in

NASDAQ:APLT - Applied Therapeutics Stock Price, Forecast & News

$20.93
-0.02 (-0.10 %)
(As of 12/12/2019 03:37 AM ET)
Today's Range
$20.33
Now: $20.93
$21.92
50-Day Range
$14.58
MA: $17.12
$24.47
52-Week Range
$7.95
Now: $20.93
$26.51
Volume48,359 shs
Average Volume31,703 shs
Market Capitalization$358.61 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLT
CUSIPN/A
CIKN/A
Phone212-220-9226

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees4
Market Cap$358.61 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive APLT News and Ratings via Email

Sign-up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.


Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics (NASDAQ:APLT) announced its earnings results on Wednesday, November, 13th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.14. View Applied Therapeutics' Earnings History.

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Applied Therapeutics.

What price target have analysts set for APLT?

4 Wall Street analysts have issued 12 month price targets for Applied Therapeutics' stock. Their forecasts range from $24.00 to $29.00. On average, they anticipate Applied Therapeutics' share price to reach $26.50 in the next year. This suggests a possible upside of 26.6% from the stock's current price. View Analyst Price Targets for Applied Therapeutics.

What is the consensus analysts' recommendation for Applied Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Therapeutics.

Has Applied Therapeutics been receiving favorable news coverage?

Media stories about APLT stock have been trending negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Applied Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Applied Therapeutics.

Are investors shorting Applied Therapeutics?

Applied Therapeutics saw a decrease in short interest in the month of November. As of November 29th, there was short interest totalling 105,000 shares, a decrease of 9.5% from the November 14th total of 116,000 shares. Based on an average daily volume of 35,900 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.4% of the company's shares are short sold. View Applied Therapeutics' Current Options Chain.

Who are some of Applied Therapeutics' key competitors?

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Allena Pharmaceuticals (ALNA), eHealth (EHTH), Iovance Biotherapeutics (IOVA), Pinterest (PINS), ADMA Biologics (ADMA), Aeglea Bio Therapeutics (AGLE), Aqua Metals (AQMS), CareDx (CDNA), Amicus Therapeutics (FOLD) and Opko Health (OPK).

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the folowing people:
  • Dr. Shoshana Shendelman Ph.D., Chairman, Founder, Pres, CEO & Sec. (Age 40)
  • Dr. Mark Joseph Vignola, Chief Financial Officer (Age 42)
  • Dr. Riccardo Perfetti, Chief Medical Officer (Age 59)

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

When did the company's lock-up period expire?

Applied Therapeutics' lock-up period expired on Monday, November 11th. Applied Therapeutics had issued 4,000,000 shares in its initial public offering on May 14th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (3.12%), Millennium Management LLC (0.15%), State Street Corp (0.06%), Emerald Advisers LLC (0.06%) and California State Teachers Retirement System (0.02%). Company insiders that own Applied Therapeutics stock include Joel S Marcus, Real Estate Equitie Alexandria and Shoshana Shendelman. View Institutional Ownership Trends for Applied Therapeutics.

Which institutional investors are selling Applied Therapeutics stock?

APLT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Applied Therapeutics.

Which institutional investors are buying Applied Therapeutics stock?

APLT stock was bought by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, State Street Corp, Emerald Advisers LLC and California State Teachers Retirement System. Company insiders that have bought Applied Therapeutics stock in the last two years include Joel S Marcus, Real Estate Equitie Alexandria and Shoshana Shendelman. View Insider Buying and Selling for Applied Therapeutics.

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $20.93.

How big of a company is Applied Therapeutics?

Applied Therapeutics has a market capitalization of $358.61 million. Applied Therapeutics employs 4 workers across the globe.View Additional Information About Applied Therapeutics.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is http://www.appliedtherapeutics.com/.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]


MarketBeat Community Rating for Applied Therapeutics (NASDAQ APLT)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about Applied Therapeutics and other stocks. Vote "Outperform" if you believe APLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel